TY - JOUR
T1 - Changes in health-related quality of life after ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins
AU - Darvall, Katy
AU - Sam, RC
AU - Bate, GR
AU - Silverman, Stanley
AU - Adam, Donald
AU - Bradbury, Andrew
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Background: Health-related quality of life (HRQOL) improves after superficial venous surgery for varicose veins, but the effect of ultrasound-guided foam sclerotherapy on HRQOL is unknown. The aim of this study was to determine changes in HRQOL after ultrasound-guided foam sclerotherapy for varicose veins.
Methods: Consecutive patients undergoing ultrasound-guided foam sclerotherapy for varicose veins were sent the Short Form 12 (SF-12) questionnaire, a generic measure of HRQOL, and the Aberdeen Varicose Vein Symptom Score (AVSS) questionnaire, a disease-specific measure of HRQOL, 1 week before treatment and 1, 6, and 12 months after treatment.
Results: The study enrolled 296 patients (34% male; 395 treated legs) with a median age of 57 years (range, 22-89 years). Of these, 24% had had previous superficial venous surgery, and 66% were CEAP C2-3 (uncomplicated varicose veins). Questionnaire completion rates were 82%, 73%, and 69% at 1, 6, and 12 months after treatment. The median Physical Component Summary score of the SF-12 (higher score indicates better HRQOL) improved from 47.6 pretreatment to 49.4 at 1 month (P <.008, Wilcoxon signed rank test), to 51.9 at 6 months (P <.0005), and to 52.9 at 12 months (P <.0005). The median AVSS (lower score indicates better HRQOL) improved from 19.0 pretreatment to 16.5 at 1 month (P <.0005), to 8.7 at 6 months (P <.0005), and to 8.6 at 12 months (P <.0005).
Conclusions: Ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins leads to significant improvements in generic and disease-specific HRQOL for at least 12 months after treatment. (J Vase Surg 2010;51: 913-20.)
AB - Background: Health-related quality of life (HRQOL) improves after superficial venous surgery for varicose veins, but the effect of ultrasound-guided foam sclerotherapy on HRQOL is unknown. The aim of this study was to determine changes in HRQOL after ultrasound-guided foam sclerotherapy for varicose veins.
Methods: Consecutive patients undergoing ultrasound-guided foam sclerotherapy for varicose veins were sent the Short Form 12 (SF-12) questionnaire, a generic measure of HRQOL, and the Aberdeen Varicose Vein Symptom Score (AVSS) questionnaire, a disease-specific measure of HRQOL, 1 week before treatment and 1, 6, and 12 months after treatment.
Results: The study enrolled 296 patients (34% male; 395 treated legs) with a median age of 57 years (range, 22-89 years). Of these, 24% had had previous superficial venous surgery, and 66% were CEAP C2-3 (uncomplicated varicose veins). Questionnaire completion rates were 82%, 73%, and 69% at 1, 6, and 12 months after treatment. The median Physical Component Summary score of the SF-12 (higher score indicates better HRQOL) improved from 47.6 pretreatment to 49.4 at 1 month (P <.008, Wilcoxon signed rank test), to 51.9 at 6 months (P <.0005), and to 52.9 at 12 months (P <.0005). The median AVSS (lower score indicates better HRQOL) improved from 19.0 pretreatment to 16.5 at 1 month (P <.0005), to 8.7 at 6 months (P <.0005), and to 8.6 at 12 months (P <.0005).
Conclusions: Ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins leads to significant improvements in generic and disease-specific HRQOL for at least 12 months after treatment. (J Vase Surg 2010;51: 913-20.)
U2 - 10.1016/j.jvs.2009.11.045
DO - 10.1016/j.jvs.2009.11.045
M3 - Article
C2 - 20347688
VL - 51
SP - 913
EP - 920
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
IS - 4
ER -